TRHC Stock Overview
Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States.
Tabula Rasa HealthCare Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.86|
|52 Week High||US$53.38|
|52 Week Low||US$2.09|
|1 Month Change||-10.44%|
|3 Month Change||-29.69%|
|1 Year Change||-91.07%|
|3 Year Change||-91.46%|
|5 Year Change||-73.45%|
|Change since IPO||-74.06%|
Recent News & Updates
Continuing To Avoid Tabula Rasa HealthCare Inc.
The problem I've been moaning about for years persists. Namely, the more Tabula Rasa HealthCare sells, the more it loses. If growing sales won't lead to profits, what will? In addition, the capital structure has deteriorated significantly since I last reviewed Tabula Rasa. The level of risk here is high, yet TRHC shares aren't cheap. If you're long, I would recommend calls in lieu of shares. These give you much of the upside as the stock, while exposing you to much less risk.
Does Tabula Rasa HealthCare (NASDAQ:TRHC) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|TRHC||US Healthcare Services||US Market|
Return vs Industry: TRHC underperformed the US Healthcare Services industry which returned -40.3% over the past year.
Return vs Market: TRHC underperformed the US Market which returned -15.1% over the past year.
|TRHC Average Weekly Movement||18.9%|
|Healthcare Services Industry Average Movement||12.5%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: TRHC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: TRHC's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems.
Tabula Rasa HealthCare Fundamentals Summary
|TRHC fundamental statistics|
Is TRHC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TRHC income statement (TTM)|
|Cost of Revenue||US$242.10m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.60|
|Net Profit Margin||-25.35%|
How did TRHC perform over the long term?See historical performance and comparison
Is Tabula Rasa HealthCare undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TRHC ($3.86) is trading below our estimate of fair value ($17.91)
Significantly Below Fair Value: TRHC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TRHC is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Healthcare Services industry average.
PE vs Market: TRHC is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TRHC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TRHC is overvalued based on its Price-To-Book Ratio (2.5x) compared to the US Healthcare Services industry average (2x).
How is Tabula Rasa HealthCare forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRHC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TRHC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TRHC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TRHC's revenue (6.6% per year) is forecast to grow slower than the US market (8% per year).
High Growth Revenue: TRHC's revenue (6.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TRHC's Return on Equity is forecast to be high in 3 years time
How has Tabula Rasa HealthCare performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TRHC is currently unprofitable.
Growing Profit Margin: TRHC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TRHC is unprofitable, and losses have increased over the past 5 years at a rate of 44% per year.
Accelerating Growth: Unable to compare TRHC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRHC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (9.5%).
Return on Equity
High ROE: TRHC has a negative Return on Equity (-237.56%), as it is currently unprofitable.
How is Tabula Rasa HealthCare's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: TRHC's short term assets ($289.1M) exceed its short term liabilities ($76.2M).
Long Term Liabilities: TRHC's short term assets ($289.1M) do not cover its long term liabilities ($394.4M).
Debt to Equity History and Analysis
Debt Level: TRHC's net debt to equity ratio (1000.2%) is considered high.
Reducing Debt: TRHC's debt to equity ratio has increased from 0% to 1040.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TRHC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TRHC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Tabula Rasa HealthCare current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TRHC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TRHC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TRHC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TRHC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TRHC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Calvin Knowlton (71 yo)
Dr. Calvin H. Knowlton, BSc Pharm, MDiv, Ph.D. ScD (Hon), is a Co-Founder of Tabula Rasa Healthcare, Inc. and has been its Chairman and Chief Executive Officer since June 2014. Dr. Knowlton founded Tabula...
CEO Compensation Analysis
Compensation vs Market: Calvin's total compensation ($USD5.97M) is above average for companies of similar size in the US market ($USD771.12K).
Compensation vs Earnings: Calvin's compensation has increased whilst the company is unprofitable.
Experienced Management: TRHC's management team is seasoned and experienced (6.7 years average tenure).
Experienced Board: TRHC's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TRHC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Tabula Rasa HealthCare, Inc.'s employee growth, exchange listings and data sources
- Name: Tabula Rasa HealthCare, Inc.
- Ticker: TRHC
- Exchange: NasdaqGM
- Founded: 2009
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: US$92.294m
- Shares outstanding: 23.91m
- Website: https://www.tabularasahealthcare.com
Number of Employees
- Tabula Rasa HealthCare, Inc.
- 228 Strawbridge Drive
- Suite 100
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/27 00:00|
|End of Day Share Price||2022/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.